Last updated: 19 June 2019 at 2:32am EST

Michael Franken Net Worth




The estimated Net Worth of Michael Franken is at least $2.05 Millón dollars as of 11 December 2015. Michael Franken owns over 520 units of Momenta Pharmaceuticals stock worth over $1,992,561 and over the last 11 years Michael sold MNTA stock worth over $62,085.

Michael Franken MNTA stock SEC Form 4 insiders trading

Michael has made over 6 trades of the Momenta Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently Michael sold 520 units of MNTA stock worth $8,237 on 11 December 2015.

The largest trade Michael's ever made was exercising 20,000 units of Momenta Pharmaceuticals stock on 10 August 2015 worth over $344,600. On average, Michael trades about 3,013 units every 46 days since 2013. As of 11 December 2015 Michael still owns at least 37,968 units of Momenta Pharmaceuticals stock.

You can see the complete history of Michael Franken stock trades at the bottom of the page.



What's Michael Franken's mailing address?

Michael's mailing address filed with the SEC is C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE, MA, 02142.

Insiders trading at Momenta Pharmaceuticals

Over the last 20 years, insiders at Momenta Pharmaceuticals have traded over $110,027,424 worth of Momenta Pharmaceuticals stock and bought 827,300 units worth $5,505,611 . The most active insiders traders include Christoph H Westphal, Craig A Wheeler y Peter Barrett. On average, Momenta Pharmaceuticals executives and independent directors trade stock every 6 days with the average trade being worth of $448,442. The most recent stock trade was executed by Ian Fier on 20 August 2020, trading 1,808 units of MNTA stock currently worth $94,323.



What does Momenta Pharmaceuticals do?

Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.



Complete history of Michael Franken stock trades at Momenta Pharmaceuticals

Persona
Trans.
Transacción
Precio total
Michael Franken
Presidente y Biosimilars Busines
Venta $8,237
11 Dec 2015
Michael Franken
Presidente y Biosimilars Busines
Venta $9,706
11 Sep 2015
Michael Franken
Presidente y Biosimilars Busines
Uso de opción $344,600
10 Aug 2015
Michael Franken
Presidente y Biosimilars Busines
Venta $11,453
11 Jun 2015
Michael Franken
Presidente y Biosimilars Busines
Venta $7,532
11 Mar 2015
Michael Franken
Presidente y Biosimilars Busines
Venta $25,158
11 Dec 2014


Momenta Pharmaceuticals executives and stock owners

Momenta Pharmaceuticals executives and other stock owners filed with the SEC include: